Structural and Functional Basis for Therapeutic Modulation of p53 Signaling
Open Access
- 15 October 2008
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (20) , 6376-6386
Abstract
Effective modulation of structural features and/or functional properties of the major tumor suppressor p53 as a wild-type or cancer-associated mutant protein represents a major challenge in drug development for cancer. p53 is an attractive target for therapeutic design because of its involvement as a mediator of growth arrest and apoptosis after exposure to chemoradiotherapy and/or radiotherapy. Although most clinically used cytotoxic agents target stabilization of wild-type p53, there are a number of approaches that hold promise for reactivation of mutant p53. On the other hand, brief blockade of p53 may reduce toxicity from systemic cytotoxic therapy. Screens for restoration of p53 transcriptional responses in p53-deficient cells may provide a functional means to develop anticancer therapeutics. Structure-based modulation continues to hold promise for development of peptides or small molecules capable of modulation of either wild-type or mutant p53 proteins.Keywords
This publication has 86 references indexed in Scilit:
- Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 ActivatorCancer Cell, 2008
- Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathwayProceedings of the National Academy of Sciences, 2008
- Hzf Determines Cell Survival upon Genotoxic Stress by Modulating p53 TransactivationCell, 2007
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenograftsProceedings of the National Academy of Sciences, 2006
- Drug discovery in the ubiquitin–proteasome systemNature Reviews Drug Discovery, 2006
- Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 InteractionJournal of Medicinal Chemistry, 2006
- Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in CellsJournal of Medicinal Chemistry, 2005
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004
- Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compoundNature Medicine, 2002